🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 15 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/09/2023 18,78 19,43 18,71 19,20 +2,89% 3,81% 980.000
25/09/2023 19,61 19,77 18,48 18,66 -5,38% 6,58% 948.600
22/09/2023 20,48 20,48 19,70 19,72 -3,24% 3,81% 719.700
21/09/2023 19,59 20,44 19,50 20,38 +2,93% 4,80% 502.900
20/09/2023 20,52 20,60 19,76 19,80 -2,80% 4,09% 392.100
19/09/2023 19,80 20,43 19,80 20,37 +2,36% 3,18% 308.700
18/09/2023 20,23 20,51 19,76 19,90 -3,26% 3,73% 795.400
15/09/2023 20,31 20,66 19,98 20,57 +1,58% 3,32% 1.176.600
14/09/2023 20,94 20,94 20,17 20,25 -2,27% 3,68% 374.500
13/09/2023 21,36 21,61 20,71 20,72 -2,49% 4,19% 371.700
12/09/2023 20,54 21,34 20,49 21,25 +2,21% 4,14% 484.000
11/09/2023 21,57 21,79 20,75 20,79 -2,76% 4,80% 464.500
08/09/2023 21,33 21,54 21,00 21,38 +0,47% 2,56% 706.100
07/09/2023 22,39 22,39 21,17 21,28 -5,42% 5,45% 870.700
06/09/2023 22,19 22,68 21,95 22,50 +2,32% 3,28% 619.800
05/09/2023 21,00 22,06 20,99 21,99 +3,73% 5,10% 899.100
01/09/2023 20,96 21,34 20,76 21,20 +3,41% 2,77% 718.600
31/08/2023 19,98 21,04 19,98 20,50 +2,04% 5,31% 1.143.300
30/08/2023 20,15 20,73 19,99 20,09 -0,45% 3,67% 1.350.000
29/08/2023 21,80 21,91 20,18 20,18 -7,26% 7,94% 1.227.600
28/08/2023 22,85 23,19 21,43 21,76 -3,67% 7,70% 1.105.500
25/08/2023 22,91 23,14 21,34 22,59 -1,44% 7,86% 1.154.200
24/08/2023 23,00 23,56 22,53 22,92 -0,48% 4,48% 1.358.800
23/08/2023 23,22 25,47 22,57 23,03 +22,43% 12,49% 4.637.900
22/08/2023 18,93 19,13 18,42 18,81 -0,84% 3,75% 437.400
21/08/2023 19,07 19,47 18,61 18,97 -0,37% 4,51% 530.200
18/08/2023 17,48 19,07 17,48 19,04 +8,06% 9,10% 677.300
17/08/2023 17,70 17,70 17,25 17,62 -0,45% 2,54% 426.400
16/08/2023 17,81 18,01 17,58 17,70 -1,50% 2,41% 421.100
15/08/2023 18,08 18,26 17,90 17,97 -0,33% 1,99% 952.600